AUG 11, 2026 · PHASE 1 TRIAL
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
ClinicalTrials.gov
This is an early-phase, first-in-human Phase 1/1b trial registration with no results posted; it is designed to establish safety, tolerability, and dose-range, not to evaluate efficacy.
Reported
Estimated enrollment178
PhasePhase 1/1b
Primary outcome measure (Part A)Incidence and severity of treatment-emergen…